||Recombinant Human Insulin-like Growth Factor Binding Protein 4 is expressed inyeast.
||Insulin-like growth factor-binding proteins (IGFBPs) control bioavailability, activity, and distribution of insulin-like growth factor (IGF) through high-affinity IGFBP/IGF complexes. Six high-affinity IGF-binding proteins (IGFBP-1 to -6) have been identified, and IGFBP4, the smallest IGFBP expressed by a wide range of cell types, exists in both non-glycosylated and N-glycosylated forms in all biological fluids. Structurally consisting of an IGFBP domain and a thyroglobulin type-I domain, IGFBP4 binds IGF-I and IGF-II with similar affinities as a transport protein and modulates their biological effects. Increasing evidences indicate that IGFBP4 inhibits IGF-induced cellular growth both in vitro and in vivo. As an important member of the IGF system, IGFBP4 is involved in a wide range of biological processes including reproductive physiology, bone formation, renal pathophysiology and carcinomas.
||Human IGF-Binding protein 4 is produced in genetically engineeredyeast, and purified by affinity chromatography and HPLC.
||The material has been judged to be >90% pure, as determined by SDS gel electrophoresis.
||Binding activity of human IGF-BP 4 is determined by the inhibition activity of both IGF-I and IGF-II.
||Lyophilized human IGF-BP 4 is stable at 4 °C for at least one year.
||Upon receipt, the material should be stored at 4 °C. Reconstitution of lyophilized IGF-BP 4 is best in water or buffer near neutral pH. After reconstitution, storage in aliquots at minus 80 °C is recommended.